UK Biotech CellCentric Raises $220M In Series D Funding

The funds will be used to advance its lead therapy, inobrodib, through pivotal clinical development, including ongoing Phase 2 DOMMINO-1 studies in the UK and US, and preparation for the global Phase 3 DOMMINO-2 trial expected to begin in the second half of 2026.

The company is also expanding the use of inobrodib into combination and maintenance treatment settings for patients with relapsed or refractory multiple myeloma.

Read Also - France’s OpsMill Raises €11.9M Series A To Improve Infrastructure Data For AI And Automation

“We are thrilled to have the support of top-tier investors who believe in inobrodib’s potential to address a critical need in multiple myeloma, notably after bispecific T cell engager or anti-BCMA therapies. This is a significant and growing unmet need,” said Will West, Ph.D., CEO of CellCentric.

“Inobrodib is a new modality and a potential fresh option for patients that is orally administered. In combination with pomalidomide and dexamethasone as InoPd, we have demonstrated deep responses in heavily pretreated relapsed or refractory multiple myeloma patients. Fueled by this funding, we are well positioned to complete registration enabling studies for the all-oral triplet and advance our progress toward delivering a transformative treatment.”

Led by CEO Will West, CellCentric is developing inobrodib, an oral p300/CBP inhibitor designed to treat relapsed or refractory multiple myeloma, with potential expansion into additional indications and combination therapies. The company operates from Cambridge, UK with an additional office in Boston, USA.

About CellCentric

CellCentric is a privately held biotech company developing inobrodib, a first-in-class oral p300/CBP inhibitor. The drug is in late-stage clinical trials for relapsed/refractory multiple myeloma. Founded in Cambridge, UK, the company operates internationally with offices in Boston and is supported by strong IP and clinical partnerships.